Abstract
There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are being investigated, at present most attention is being paid to two classes of epigenetic drugs: drugs that inhibit DNA methyltransferase (DNMTi) and drugs that inhibit histone deacetylase (HDACi). This paper discusses the potential use of epigenetic drugs in the treatment of MS, focusing on DNMTi and HDACi. Preclinical drug trials of DNMTi and HDACi for the treatment of MS are showing promising results. Epigenetic drugs could improve the clinical management of patients with MS.
Keywords: DNA methyltransferase inhibitor, epigenetic, histone deacetylase inhibitor, multiple sclerosis.
Current Neuropharmacology
Title:Epigenetic Drugs for Multiple Sclerosis
Volume: 14 Issue: 1
Author(s): Jacob Peedicayil
Affiliation:
Keywords: DNA methyltransferase inhibitor, epigenetic, histone deacetylase inhibitor, multiple sclerosis.
Abstract: There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are being investigated, at present most attention is being paid to two classes of epigenetic drugs: drugs that inhibit DNA methyltransferase (DNMTi) and drugs that inhibit histone deacetylase (HDACi). This paper discusses the potential use of epigenetic drugs in the treatment of MS, focusing on DNMTi and HDACi. Preclinical drug trials of DNMTi and HDACi for the treatment of MS are showing promising results. Epigenetic drugs could improve the clinical management of patients with MS.
Export Options
About this article
Cite this article as:
Peedicayil Jacob, Epigenetic Drugs for Multiple Sclerosis, Current Neuropharmacology 2016; 14 (1) . https://dx.doi.org/10.2174/1570159X13666150211001600
DOI https://dx.doi.org/10.2174/1570159X13666150211001600 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Parallel Synthesis of “Click” Chalcones as Antitubulin Agents
Medicinal Chemistry Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Neurorescue Activity, APP Regulation and Amyloid-β Peptide Reduction by Novel Multi-Functional Brain Permeable Iron- Chelating- Antioxidants,M-30 and Green Tea Polyphenol, EGCG
Current Alzheimer Research Chemopreventive Properties of Peptide Lunasin: A Review
Protein & Peptide Letters Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§
Current Medicinal Chemistry Histopathology Image Analysis and Classification Using ARMA Models: Application to Brain Cancer Detection
Current Medical Imaging Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Current Neuropharmacology Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Neuron Protection as a Therapeutic Target in Acute Ischemic Stroke
Current Topics in Medicinal Chemistry Resveratrol and Its Analogues: Promising Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Mechanisms of Prion Protein Aggregation
Protein & Peptide Letters Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Intra-arterial Instillation of a Nociceptive Agent Modulates Cardiorespiratory Parameters Involving 5-HT3 and TRPV1 Receptors in Anesthetized Rats
Cardiovascular & Hematological Disorders-Drug Targets Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Current Pharmaceutical Design Histone Modifications, Stem Cells and Prostate Cancer
Current Pharmaceutical Design Conformation as the Therapeutic Target for Neurodegenerative Diseases
Current Alzheimer Research Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry